C WorldWide Group Holding A/S - KARYOPHARM THERAPEUTICS INC ownership

KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 171 filers reported holding KARYOPHARM THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.47 and the average weighting 0.2%.

Quarter-by-quarter ownership
C WorldWide Group Holding A/S ownership history of KARYOPHARM THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,010
-25.1%
1,500,0000.0%0.03%
-22.9%
Q2 2023$2,685
-54.0%
1,500,0000.0%0.04%
-56.2%
Q1 2023$5,835
+14.4%
1,500,0000.0%0.08%
+17.6%
Q4 2022$5,100
-99.9%
1,500,0000.0%0.07%
-39.8%
Q3 2022$8,190,000
+21.1%
1,500,0000.0%0.11%
+32.9%
Q2 2022$6,765,000
-38.8%
1,500,0000.0%0.08%
-29.2%
Q1 2022$11,055,000
+14.6%
1,500,0000.0%0.12%
+31.9%
Q4 2021$9,645,000
+38.1%
1,500,000
+25.0%
0.09%
+26.4%
Q3 2021$6,984,000
-43.6%
1,200,0000.0%0.07%
-43.8%
Q2 2021$12,384,000
-1.9%
1,200,0000.0%0.13%
+3.2%
Q1 2021$12,624,000
+35.9%
1,200,000
+100.0%
0.12%
+33.3%
Q4 2020$9,288,000
+2886.5%
600,000
+3187.9%
0.09%
+2225.0%
Q3 2018$311,000
+17.4%
18,249
+16.9%
0.00%0.0%
Q2 2018$265,000
+26.2%
15,6120.0%0.00%
+33.3%
Q1 2018$210,000
+36.4%
15,612
-2.7%
0.00%
+50.0%
Q4 2017$154,000
-24.1%
16,048
-13.3%
0.00%
-33.3%
Q3 2017$203,000
+43.0%
18,515
+18.1%
0.00%
+50.0%
Q2 2017$142,000
-34.6%
15,678
-7.4%
0.00%
-50.0%
Q1 2017$217,000
+77.9%
16,928
+30.2%
0.00%
+100.0%
Q4 2016$122,00013,0000.00%
Other shareholders
KARYOPHARM THERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
Consonance Capital Management LP 7,180,700$137,941,00010.27%
Palo Alto Investors LP 4,299,901$82,601,0006.92%
Fairmount Funds Management LLC 562,351$10,803,0006.55%
Avoro Capital Advisors LLC 7,000,000$134,470,0004.54%
Pinz Capital Management, LP 8,820$1,694,0004.44%
Birchview Capital, LP 148,000$2,843,0002.52%
Elk Creek Partners, LLC 699,951$13,446,0002.31%
Parkman Healthcare Partners LLC 215,802$4,146,0001.92%
EAM Global Investors LLC 136,402$2,620,0001.53%
SPHERA FUNDS MANAGEMENT LTD. 550,000$10,566,0001.32%
View complete list of KARYOPHARM THERAPEUTICS INC shareholders